atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression Seite 1
27.03.2024 - - A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of ... Seite 1
Source: wallstreet-online.de